The safety and efficacy of intracameral moxifloxacin (IC-Mox) use in adult lens surgery has been established, as had been efficacy in pediatric surgery. But what about safety in the younger group? Sina Khalili, MD, a research fellow in the department of ophthalmology and vision sciences at The Hospital for Sick Children in Toronto, and colleagues set, out to find the answer. Dr. Khalili presented the results of a retrospective study in a poster during the American Academy of Ophthalmology’s 2018 annual meeting in Chicago.
Participants, who averaged ~5 years of age and had lens-related surgery, received either IC-Mox (n=170) or subconjunctival antibiotics (SC-Ab; n=150). Investigators measured best corrected visual acuity (BCVA), intraocular pressure (IOP), central corneal thickness (CCT), and endothelial cell density (ECD) preoperatively. They then looked at IOP, corneal edema, and anterior cells and flare within the first 6 weeks; CCT at 3 months; ECD at 1 year; and IOP and BCVA at the last visit.
They found no differences in IOP, BCVA, CCT, ECD, corneal edema, and AC inflammation measures between the two groups, thus concluding that IC-Mox can be used routinely in pediatric patients, similar to adult cataract surgery.
Khalili S, Imtirat A, William S, Tehrani N, Ali A, Mireskandari K. Safety of intracameral moxifloxacin in pediatric lens surgery: An equivalence study. Poster presented at: AAO 2018 annual meeting; October, 26-30, 2018; Chicago.